From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.
ADCs have transformed bladder cancer treatment, but challenges like toxicity management and high costs remain significant hurdles. ADCs vary in components and mechanisms, influencing outcomes and ...
The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results